Answer
Yes. BCR-ABL inhibitors can reactivate previous hepatitis B infection, so screening is required before treatment and carriers need continued monitoring.
Sources for this answer
- Dasatinib 140 mg Film-coated Tablets — Current selected SmPCemc · Summary of Product Characteristics
- UK GovernmentUK Government · Reputable Web
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.